The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma

Abstract

BackgroundTo investigate the value of dynamic monitoring peripheral blood lymphocyte-to-monocyte (LMR) ratio in evaluating the treatment response and prognosis of patients with extranodal NK/T cell lymphoma (ENKTL).MethodsA total of 148 patients with ENKTL were retrospectively analyzed in the Affiliated Tumor Hospital of Zhengzhou University between March 2012 and March 2018. The optimal cut-off value of LMR was determined using the receiver operating characteristic curve (ROC) method, then patients were divided into low LMR group and high LMR group. The LMR level was dynamically measured at various time points, and the relationships between LMR and therapeutic response, and survival were analyzed.ResultsThe complete remission rate (CR) was 85.7% in patients with high LMR at diagnosis, which was remarkably higher than that of patients with low LMR at diagnosis (64.9%) (P = 0.009). The 5-year overall survival (OS) and progression-free survival (PFS) were 49.28% and 44.89% in the low LMR group, respectively; 5-year OS and PFS in the high LMR group were 84.50% and 67.12%, respectively, significantly longer (P values were < 0.001 and 0.034, respectively). The OS and PFS of patients with elevated LMR after treatment were longer than those with decreased LMR after treatment (all P values < 0.05). The LMRs at relapse were significantly lower in both high and low LMR groups than those of the last follow-up (P values were 0.001 and 0.016, respectively). Univariate and multivariate analysis demonstrated that low LMR was an independent risk factor for poor prognosis in ENKTL patients (P values were < 0.001 and 0.009, respectively).ConclusionsLymphocyte to monocyte ratio can be used as an indicator of treatment response, prognosis and recurrence in patients with ENKTL. Low LMR before and after treatment is a poor prognostic factor.

The Predictive Value of the Peripheral Blood Lymphocyte-to-Monocyte Ratio in Patients with Anaplastic Large Cell Lymphoma

“…The CCR rate and survival of ALK-positive patients were signi cantly better than that for ALKnegative patients in this study, which is in line with the literature [8]. Recently, the baseline LMR has also been con rmed to have potential prognostic value for various malignant diseases [21][22][23][24][25]. Herein, we investigated the prognostic signi cance of baseline LMR independent or combined with ALK expression in a cohort of 103 ALCL patients.…”

“…A decreased LMR may re ect an innately dysfunctional host immune response, or a byproduct of tumor-related immune suppression [19]. Moreover, the low LMR is associated with the poor OS and PFS of patients, which has been con rmed in Hodgkin's lymphoma and a variety of non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and NK/T-cell lymphoma [20][21][22][23][24][25]. However, the predictive value of the LMR has not been fully characterized in patients with ALCL.…”

Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

“…No more than 1 week prior to enrollment, the baseline hematological index was collected, including routine blood examination, biochemical data, blood coagulation indices, etc. We adopted the commonly used method of using a receiver operating characteristic (ROC) curve to calculate cut-off values for survival [8][9][10][11][12] . PFS and OS measurements were obtained using survival status (dead or alive), and imaging findings were used to determine condition (progression or stable) at the end of the follow-up; these measurements were considered as outcome variables and were also compared to their respective normal clinical values to confirm reliability.…”

Prognostic Value of Peripheral Blood Lymphocyte/monocyte Ratio in Lymphoma

“…The clinical outcomes of many lymphoma subtypes, including FL [8,9], DLBCL [10,11], and NK/TL [12], could be predicted by peripheral blood LMR. Due to the heterogeneity of the sample size and the diversity of treatments reported in previous studies, the consistency of the prognostic impact of LMR remains unknown.…”